We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.

Valneva USA Inc. is focused on the marketing and distribution of Valneva’s vaccine for Chikungunya and Japanese Encephalitis.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, …

Our R&D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines. We want to make a …

3 天之前 · French vaccine maker Valneva won a $32.8 million contract to supply the U.S. Department of Defense with vaccines to treat Japanese encephalitis, which is endemic in …

6 天之前 · Saint Herblain (France), January 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million …

2025年1月30日 · Valneva (VLNV) stock picks up as company signs $32.8M contract with U.S. Department of Defense to supply its Japanese encephalitis vaccine, Ixiaro. Read more here.

2 天之前 · UK's Medicines and Healthcare products Regulatory Agency approved Valneva's IXCHIQ vaccine against Chikungunya disease, which is caused by the chikungunya virus that …

Tonnes de CO₂ émises par million d’euros de revenu généré : 19,0. Niveau de controverse : Négligeable. Implications dans des activités ayant un impact positif : 0/12. Implications dans …

Identify vulnerabilities, prioritize risk, and validate remediation in one place. VULNERA closes the detection – remediation loop in vulnerability management.